| scholarly article | Q13442814 |
| P50 | author | Jessica Roelands | Q56806038 |
| Francesco Marincola | Q107723823 | ||
| P2093 | author name string | Thomas J Hudson | |
| Davide Bedognetti | |||
| Howard J Jacob | |||
| Michele Ceccarelli | |||
| Kyle Halliwill | |||
| Sarah Kongpachith | |||
| Josue Samayoa | |||
| Tolga Turan | |||
| Wouter Hendricks | |||
| P2860 | cites work | The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures | Q27015137 |
| Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. | Q27853339 | ||
| Comprehensive molecular profiling of lung adenocarcinoma | Q28244995 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups | Q29614700 | ||
| Supervised risk predictor of breast cancer based on intrinsic subtypes | Q29617404 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| The immune contexture in human tumours: impact on clinical outcome | Q29620667 | ||
| Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer | Q29620913 | ||
| Inferring tumour purity and stromal and immune cell admixture from expression data | Q30674996 | ||
| TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data | Q31034005 | ||
| Indicators of responsiveness to immune checkpoint inhibitors | Q33678048 | ||
| Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. | Q36553576 | ||
| The prognostic landscape of genes and infiltrating immune cells across human cancers | Q36857285 | ||
| Molecular and genetic properties of tumors associated with local immune cytolytic activity | Q36869059 | ||
| Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance | Q36891038 | ||
| Transforming growth factor-beta and the immune response: implications for anticancer therapy | Q36944384 | ||
| Combining FoxP3 and Helios with GARP/LAP markers can identify expanded Treg subsets in cancer patients. | Q37046528 | ||
| A landscape of pharmacogenomic interactions in cancer. | Q37140236 | ||
| Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis | Q37234841 | ||
| Genomic correlates of response to CTLA-4 blockade in metastatic melanoma | Q37319470 | ||
| Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. | Q37683769 | ||
| Identification of Interacting Stromal Axes in Triple-Negative Breast Cancer | Q38431992 | ||
| Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma | Q38453759 | ||
| IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. | Q38709131 | ||
| Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade | Q38727885 | ||
| Disentangling the relationship between tumor genetic programs and immune responsiveness | Q38770041 | ||
| Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. | Q38875037 | ||
| Emerging Biological Principles of Metastasis | Q39130446 | ||
| Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha | Q39635625 | ||
| Analysis of PI3K pathway components in human cancers. | Q39655215 | ||
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial | Q40163779 | ||
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity | Q40944056 | ||
| Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer | Q41550474 | ||
| Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer | Q41701208 | ||
| Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. | Q41974388 | ||
| Epithelial-mesenchymal transition in cancer | Q42332304 | ||
| Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells | Q42581359 | ||
| Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab | Q45070125 | ||
| A metabolic function of FGFR3-TACC3 gene fusions in cancer. | Q47660101 | ||
| TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. | Q50001757 | ||
| Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. | Q50954469 | ||
| The Immune Landscape of Cancer. | Q52720878 | ||
| Immune oncology, immune responsiveness and the theory of everything. | Q55487467 | ||
| Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). | Q55497366 | ||
| RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade | Q56888903 | ||
| Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma | Q56889995 | ||
| Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response | Q56890003 | ||
| Genetic basis for clinical response to CTLA-4 blockade | Q56896235 | ||
| The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer | Q57790346 | ||
| Regularization and variable selection via the elastic net | Q62065858 | ||
| The combination of neoantigen quality and T lymphocyte infiltrates identifies glioblastomas with the longest survival | Q64096613 | ||
| EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small cell lung cancer | Q64109081 | ||
| Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma | Q89931916 | ||
| PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition | Q89993630 | ||
| Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma | Q91451443 | ||
| Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy | Q91503293 | ||
| Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response | Q94590453 | ||
| Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells | Q96017659 | ||
| A map of tumor-host interactions in glioma at single-cell resolution | Q101404013 | ||
| P4510 | describes a project that uses | Cytoscape | Q3699942 |
| GEOquery | Q114076475 | ||
| P577 | publication date | 2020-11-03 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival |
Search more.